<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127618">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01735175</url>
  </required_header>
  <id_info>
    <org_study_id>LA-EP06-301</org_study_id>
    <secondary_id>2011-004532-58</secondary_id>
    <nct_id>NCT01735175</nct_id>
  </id_info>
  <brief_title>Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®</brief_title>
  <acronym>PROTECT 1</acronym>
  <official_title>A Randomized, Double-blind, Parallel-group, Multi-center Phase 3 Comparative Study Investigating Efficacy and Safety of LA-EP2006 and Neulasta® in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the efficacy of LA-EP2006 compared to Peg-Filgrastim with respect to
      the mean duration of severe neutropenia during treatment with myelosuppressive chemotherapy
      in breast cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Mean duration of Grade 4 neutropenia during Cycle 1 of chemotherapy</measure>
    <time_frame>21 days (Cycle 1 of chemotherapy treatment)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Mean duration of severe neutropenia, defined as number of consecutive days with Grade 4 neutropenia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of febrile neutropenia</measure>
    <time_frame>4 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess the safety of LA-EP2006 and Peg-Filgrastim.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, occurrence and severity of (serious) adverse events.</measure>
    <time_frame>10 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">318</enrollment>
  <condition>Neutropenic Complications</condition>
  <condition>Breast Cancer Patients Treated With Myelosuppressive Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Peg-Filgrastim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During each chemotherapy cycle eligible patients receive Peg-Filgrastim s.c. post chemotherapy application.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LA-EP2006</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LA-EP2006</intervention_name>
    <description>Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.</description>
    <arm_group_label>LA-EP2006</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg-Filgrastim</intervention_name>
    <description>Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.</description>
    <arm_group_label>Peg-Filgrastim</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically proven breast cancer

          -  eligible for six cycles of neoadjuvant or adjuvant chemotherapy

        Exclusion Criteria:

          -  concurrent or prior chemotherapy for breast cancer

          -  concurrent or prior anti-cancer treatment for breast cancer such as endocrine
             therapy, immunotherapy, monoclonal antibodies, and/or biological therapy

          -  concurrent prophylactic antibiotics

          -  previous therapy with any G-CSF (granulocyte-colony stimulating factor) product

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karsten Roth, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Sandoz Biopharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regional Budgetary Healthcare Institution &quot;Kursk Regional Clinical Oncological Dispensary&quot; of Committee Healthcare of Kursk Territory, Russia</name>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>September 20, 2013</lastchanged_date>
  <firstreceived_date>November 22, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention of neutropenic complications in breast cancer patients</keyword>
  <keyword>Pegfilgrastim,</keyword>
  <keyword>G-CSF,</keyword>
  <keyword>neutropenia,</keyword>
  <keyword>breast cancer,</keyword>
  <keyword>myelosuppressive chemotherapy,</keyword>
  <keyword>supportive care</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
